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Abstract
Background: Human intravenous immunoglobulin (hIVIG) preparation is indicated for treating primary
immunodeficiency disorders associated with impaired humoral immunity. hIVIG is known for its anti-inflammatory
properties and a decent safety profile. Therefore, by virtue of its constituent natural anti-amyloid beta antibodies
and anti-inflammatory effects, hIVIG is deemed to mediate beneficial effects to patients of Alzheimer’s disease (AD).
Here, we set out to explore the effects of hIVIG in a mouse model of AD.
Methods: We treated APP/PS1dE9 transgenic and wild-type mice with weekly injections of a high hIVIG dose (1 g/
kg) or saline for 3 or 8 months. Treatment effect on brain amyloid pathology and microglial reactivity was assessed
by ELISA, immunohistochemistry, RT-PCR, and confocal microscopy.
Results: We found no evidence for reduction in Aβ pathology; instead 8 months of hIVIG treatment significantly
increased soluble levels of Aβ40 and Aβ42. In addition, we noticed a significant reduction in CD45 and elevation of
Iba-1 markers in specific sub-populations of microglial cells. Long-term hIVIG treatment also resulted in significant
suppression of TNF-α and increase in doublecortin positive adult-born neurons in the dentate gyrus.
Conclusions: Our data indicate limited ability of hIVIG to impact amyloid burden but shows changes in microglia,
pro-inflammatory gene expression, and neurogenic effects. Immunomodulation by hIVIG may account for its
beneficial effect in AD patients.
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Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease that poses enormous social, economical, and
emotional burden on the resources of both developed
and developing countries. Presence of amyloid-β (Aβ)
deposits, neurofibrillary tangles, and neuronal loss in
brain areas responsible for maintenance of cognitive
functions are primary hallmarks of AD. According to
amyloid cascade hypothesis [1], Aβ protein inside brain
unleashes a cascade of downstream events that ultimately
results in loss of synapses and neurons. However, it is still
not clear whether Aβ is a trigger or a driver of AD path-
ology. One important consequence of Aβ deposition in
the brain tissue is neuroinflammation. Phagocytic or
macropinocytic activation of resident microglia and
macrophages around amyloid deposits can be seen as a
protective response, since there is substantial evidence
for their involvement in the clearance of extracellular Aβ
[2]. On the other hand, neuroinflammation may as well
facilitate development of amyloid plaque pathology [3].
In addition, release of pro-inflammatory cytokines may
contribute to the dysfunction and neurodegeneration.
For instance, pro-inflammatory cytokines TNF-α and IL-
1β impair synaptic plasticity and thereby can induce
memory impairment, while anti-inflammatory cytokine
IL-4 has an opposite effect [4,5]. There is evidence that
these two effects of microglial activation may be differen-
tially regulated. For instance, while phagocytosis of Aβ is
the dominant response in young mice with amyloid
deposits, in aged mice phagocytosis associated gene
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expression decreases while that of pro-inflammatory
cytokines increases [6]. There is also evidence that des-
pite accumulation around amyloid plaques microglia
seem to be incapable of Aβ phagocytosis unless specific-
ally activated [7]. One way to induce putative beneficial
activation in microglia is either by active or passive im-
munotherapy. Active immunization with Aβ has proved
to be an efficient way to reduce brain amyloid load in
APP transgenic mouse models of AD [8-10], but their
first clinical trials needed to be discontinued due to de-
velopment of fulminant meningo-encephalitis in a con-
siderable number of patients [11]. Also passive
immunization with monoclonal antibodies reactive to N-
terminal, middle portion, or C-terminal of Aβ protein
have proven to be effective in AD mouse models [12-14]
and are currently in various phases of clinical develop-
ment. However, also passive immunotherapy bears the
risk of microhemorrhages [15]. In addition, all clinical
trials so far with monoclonal Aβ antibodies have yielded
meager benefit for the patients [16].
Human intravenous immunoglogulins (hIVIG), a
spectrum of polyclonal natural antibodies, have a long
history of being a safe and effective treatment for cer-
tain neurological conditions such as Guillain-Barré syn-
drome [17]. Constituent antibodies of hIVIG are
reactive to a plethora of inflammatory proteins and their
mediators. In addition, a small fraction of antibodies in
hIVIG are reactive to Aβ protein [18], which has
encouraged clinical trials to test hIVIG in AD patients.
Indeed, several studies with a small patient number
have produced promising effects on Aβ levels in the
CSF and also some positive effects on cognitive status
of AD patients [19,20]. Mechanistically, hIVIG is
hypothesized to promote Aβ clearance by virtue of its
constituent anti-Aβ antibodies, which can account for
its beneficial effect in AD patients. In addition, due to
its anti-inflammatory properties hIVIG may modulate
the neuroinflammatory reaction around amyloid pla-
ques towards neuroprotective direction and thereby me-
diate beneficial effects in AD patients. Clearly, there is
an urgent need to test the mechanisms of hIVIG action
in an animal model of AD.
Our previous studies [21] indicate that it is indeed
possible to study the biological effects of hIVIG in the
human CNS using a mouse model. As expected, mice
develop neutralizing antibodies towards human IgG,
but prolonged treatments produced immunotolerance.
Furthermore, hIVIG is capable to cross the mouse
blood–brain barrier and reach significant concentra-
tions especially in the septal (dorsal) hippocampus
aligning the lateral ventricles. We also reported that
systemic administration results in decoration of amyloid
plaques with hIVIG in the hippocampus [21]. In the
current study, we treated 4-month-old APP/PS1dE9 mice
with weekly injections of a high hIVIG dose (1 g/kg) for
either 3 months or 8 months and assessed its impact
on amyloid pathology and neuroinflammation. These
mice develop amyloid plaques with a dense Congo red
positive core and diffuse outer layer, closely resembling
amyloid plaques in AD brains [22]. The first plaques
appear in the neocortex and hippocampus around
4 months of age, followed by a rapid accumulation until
11 to 12 months of age [23]. The longer treatment thus
covered the entire period of rapid amyloid plaque for-
mation. Nevertheless, even the longer hIVIG treatment
did not reduce amyloid deposition but induced selective
immunomodulation and enhanced neurogenesis, which
both may be significant for the beneficial clinical effects
of hIVIG in AD patients.
Materials and Methods
Animals and experimental design
Four-month-old female APPswe/PS1dE9 (APP/PS1dE9)
transgenic and their wild-type littermates were used.
APP/PS1dE9 mice harbor human APPswe mutation
(K595N and M596L) and human PS1 with deletion of
exon 9 co-integrated in the same transgene [22]. The
mice were backcrossed for nine generations to C57BL/
6 J mice. APP/PS1dE9 mice develop progressive amyloid
pathology beginning as early as 4 months of age and
cognitive deficits around 12 months of age [23]. The
housing conditions (National Animal Center, Kuopio,
Finland) were controlled (temperature +22 °C, light from
07:00 to 19:00; humidity 50-60%), and fresh food and
water were freely available. The experiments were con-
ducted according to the Council of Europe (Directive
86/609) and Finnish guidelines, and approved by the
State Provincial Office of Eastern Finland.
We ran two experiments with treatment durations of
3 months and 8 months, beginning at the age of
4 months (Figure 1A). Mice were randomly assigned to
either hIVIG (Gammagard Liquid, Baxter A/G, Austria;
n= 16) or saline (10 mL/kg; n= 15) treatments, and
received weekly intraperitoneal injections. The dose
(1 g/kg) and treatment schedule was chosen based on
our initial pilot studies. Throughout the treatment
period mice were housed individually in cages. Mice
were regularly assessed for weight loss, signs of pain,
and distress due to treatments. Apart from tenderness
and heightened tactile sensitivity around the site of
injection, there were no other untoward behavioral or
pathological consequences of chronic hIVIG treatment.
A week after the last hIVIG injection, mice were
euthanized with an overdose of pentobarbiturate-
chloralhydrate injection. Terminal blood sample was
collected with a cardiac puncture for assays of serum Aβ
and anti-human IgG levels. Mice were then transcardially
perfused with ice-cold saline. Brains were rapidly










Figure 1 (See legend on next page.)
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removed, subsequently one hemibrain was dissected on
ice into three cortical (frontal, parietal, temporal) blocks
and one hippocampal block, and snap frozen in liquid
nitrogen. The other hemibrain was immersion fixed in
4% paraformaldehyde solution for 4 h followed by 30%
sucrose overnight. Fresh frozen brains samples were
stored at -70°C until used, whereas fixed hemibrains were
stored in anti-freeze at -20°C for later immunohistology.
Histochemistry
Coronal sections of 35 μm were cut with a freezing slide
microtome. Following systematic random sampling
scheme, four free-floating sections 400 μm apart from
each other, starting from septal hippocampus (-1.3 mm
from bregma) were stained with primary antibodies
6E10 (1:2,000; Senetek), WO2 (1:30,000; Genetics) for
Aβ, and with CD45 (1:1,000; Serotec), CD68 (1:5,000;
Serotec), Iba-1 (1:5,000;Wako) for microglia. Astrocytes
were stained with GFAP primary antibody (1:1,000;
Sigma). Similarly, six to seven sections each 210 μm
apart starting from septal hippocampus (-1.3 mm from
bregma) were stained with doublecortin antibody
(1:1,000; Santa Cruz) to visualize newly-born neurons.
Corresponding biotinylated anti-rat, anti-mouse, anti-
rabbit, and anti-goat secondary antibodies (1:500) were
used followed by incubation with HRP labeled Streptavi-
din. Color was developed by reacting nickel diaminoben-
zidine with hydrogen peroxide. Reaction was stopped
with phosphate buffer and sections were then mounted,
cleared in xylene, and coverslipped. For double fluores-
cent stainings, sections were sequentially incubated with
CD45 followed by Iba-1 primary antibodies. Tyramide
signal amplification kit (Molecular Probes) was used
for visualizing CD45 with cy-3 label, whereas Alexa
Fluor488 conjugated secondary antibody (1:400;
Molecular Probes) was used for Iba-1 staining. Anti-
human IgG immunostaining were performed as
described in our earlier report [21]. For Congo red
staining, sections mounted on slides were incubated in
saturated alcoholic alkaline NaCl solution for 20 min,
followed by incubation in alkaline solution of 0.2% al-
coholic Congo red solution. Slides were then washed,
dehydrated, cleared in xylene, and coverslipped.
Image acquisition and analysis
Images (2074 × 2074) from hippocampi were acquired at
2× (Plan N2×/0.06) objective using an upright optical
microscope (OLYMPUS BX40) with Olympus optical
DP50 camera. A flat field image was also acquired in
order to correct uneven illumination. Immunopositive
areas were quantified using Photoshop CS3 Extended
version 10 software (Adobe Systems Incorporated, San
Jose, CA, USA). Briefly, hippocampus (the region of inter-
est) was outlined and the immunopositive areas were thre-
sholded for measurements and reported as mean percent
immunopositive area for each brain. For double-stained
fluorescent sections, images were acquired with confocal
Zeiss LSM 700 microscope. Eight bit images stacks
(1024× 1024) were taken with Plan-Apochromat 40×/1.3
oil DIC M27 objective. Individual pixel size in x-y direc-
tion was 0.31 μm and 0.41 to 0.49 μm along the z-axis.
Subsequent image analysis was done by Image J software.
After background subtraction, individual microglial cell
stacks were outlined and separated in x-, y-, and z-planes.
Each stack was then split into its constituent green, red,
and blue channels. A simple Image J macro then applied a
threshold value for red and green channels, and created
selections for measurements of integrated densities, vol-
ume, and areas. Maximum intensity projections of micro-
glial cell stacks were then used to measure circularity.
(See figure on previous page.)
Figure 1 Experiment timeline and anti-human IgG tires. (A) Four-month-old APdE9 transgenic mice and their wild-type littermates received
once weekly intraperitoneal injection of either hIVIG (1 g/kg) or saline for 3 months (Experiment 1) or for 8 months (Experiment 2). Mice were
sacrificed one week after the last injection and brain samples were collected. In Experiment 2, blood samples were also collected at 7.5 months
(upward arrows). (B) Anti-human IgG titers developed by APdE9 mice treated for 3 months with hIVIG (n= 17) compared to saline (n= 2). Sera
were collected at the end of treatment period and anti-human IgG titers were estimated by ELISA. Titers are expressed in log10 scale and titers
only> 200 were considered significant. (C) Anti-human IgG titers developed at 6 and 12 month’s time point by 4-month-old female APdE9
(n= 16) and wild-type (n= 16) mice, treated for 8 months with hIVIG compared to saline (n= 4; one for each genotype at 6 and 12 months of
age). Titers> 200 were considered significant. Circles and triangles represent wild and APdE9 mice, respectively. It is evident from (B) and (C) that
not all mice developed significant anti-human IgG titers. Moreover, at terminal sampling point anti-human IgG titers were highly variable
irrespective of genotype or treatment duration. (D) Brain sections stained with anti-human IgG antibody and the corresponding anti-human IgG
titres in sera as measured by ELISA are shown here. Notice similar patterns of human IgG immunopositivity in hippocampus as we proceed from
titres of 50 to as high as 51,200. Scale bar denotes 100 μm. (E) Coronal brain section immunostained with anti-human IgG antibody. The full
extent of human IgG penetration in this mouse 389 with highest anti-human IgG titres is displayed. Scale bar denotes 500 μm. Black and red
arrows highlight hippocampal and cortical human IgG immunopositivity, respectively. (F) One of the sections from a pair of serial sections is
stained with anti-human IgG antibody and the other with double stain for anti-human IgG/congo red. Brain penetration of hIVIG is clearly evident
from the presence of numerous hIgG deposits in the hippocampus (red arrows). These hIgG deposits are seen decorating congo red positive
amyloid deposits (black arrows). Scale bar denotes 50 μm.
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Assay for anti-human IgG antibodies
Microtiter plates (PolySorp, Nunc) were coated with
Gammagard Liquid (Baxter AG, Austria) diluted to
1 μg/mL with coating buffer containing NaHCO3
(0.1 M; Merck) and Na2CO3 (0.1 M; Merck), adjusted to
pH9.6. After overnight incubation and washing with a
buffer of Dulbecco’s PBS (Gibco Life Technologies) sup-
plemented with Tween20 (0.05%; Merck), the plates
were blocked with the same buffer plus 1% BSA for 2 h
at room temperature. After further washing, dilutions of
serum samples and controls were added to the plates
and incubated for 2 h at room temperature. Serum sam-
ples and the negative control (serum pooled from un-
treated mice) were pre-diluted at 1:50 in the same
buffer but with 0.5% BSA and further serially diluted by
a factor of 2. Purified mouse anti-human IgG Fc (Jack-
son) was pre-diluted 1:250,000 and further serially
diluted by a factor of 2 for the positive control of the
assay. After washings, the plates were incubated with
HRP-conjugated goat anti-murine IgG (1:2,000; South-
ern Biotech) for 1 h at room temperature. Further wash-
ing and incubation with enzyme substrate (substrate
buffer: Na2HPO4.2H2O (0.1 M; Merck), C6H8O7.H2O
(0.05 M; Merck), pH5.0, o-phenylenediamine-dihy-
drochloride (1 mg/mL; Sigma), and H2O2 (0.03%;
Merck)) for 30 min at room temperature produced a
color reaction. The reaction was stopped with H2SO4
(2 N; Merck) and the color intensity was measured with
an ELISA plate reader (Synergy BioTek) set at a 492-nm
wavelength (wavelength correction set to 630 nm). All
samples where the difference between the samples’ OD
and the blank OD was≥ 0.3 were considered positive.
The highest dilution to show a positive result was speci-
fied as the titer.
ELISA assays of amyloid-β
For estimating serum Aβ40 levels, serum samples were
diluted at 1:3 with diluting buffer in accordance to the
instructions of commercial high sensitivity ELISA kit
(The Genetics Company, Switzerland). Standards or
diluted samples and antibody conjugate comprising of a
detection antibody were applied to the 96-well microti-
ter plates precoated with capture antibody. Following
overnight incubations at 4 °C and washings, biotin-strep-
tavidin enzyme conjugate was incubated at room
temperature for 30 min. A further incubation with en-
zyme substrate at room temperature for 30 min gave a
colored reaction product. After stopping the reaction,
color intensity was measured with a microtiter ELISA
plate reader (Labsystem Multiskan MS) set at 450 nm
wavelength. Standard curve was prepared and sample
concentrations of Aβ40 were extracted from standard
curve and expressed as pg per mL of serum.
Levels of soluble and insoluble Aβ40 and Aβ42 were
determined from the hippocampus block. The tissue was
weighed and homogenized in 10× volume of Dulbecco’s
PBS buffer (SIGMA), containing complete inhibitory
mixture (Roche Diagnostics, Germany). Samples were
centrifuged at 45,000 rpm (Beckman Ultrafuge) for 2 h
at 4 °C. Supernatant was diluted at 1:2 and used to
analyze soluble levels of Aβ40 and Aβ42. The remaining
pellet was resuspended in 5 M guanidine-HCl/50 mM
TrisHCl, pH 8.0 and mixed on a shaker for 3 h at RT.
Samples were then diluted at 1:50 with reaction buffer
(Dulbecco’s PBS with 5% BSA, 0.03% tween-20, supple-
mented with protease inhibitor cocktail) and centrifuged
at 16,000 × g for 20 min at 4 °C. Decanted supernantant
is further diluted at 1:400 with dilution buffer. Diluted
samples were then used to analyze insoluble Aβ40
and42 species. Aβ40 and Aβ42 levels were estimated
using ELISA kits (Biosource International) in accordance
to manufacturer’s instructions. Aβ40 andAβ42 levels
were standardized to tissue weight and expressed as
picograms of Aβ per gram± SEM.
Real-time PCR
Total RNA was extracted from frozen frontal cortices by
TRIzol reagent (Invitrogen) according to the manufac-
turer’s instructions. RNA concentration and purity was
measured with Nanodrop 1,000 spectrophotometer
(Thermo Fisher Scientific). cDNA was synthesized from
500 ng of total RNA using random hexamer primers
(Promega) as a template and Maxima reverse transcript-
ase (all reagents from Fermentas). The relative expres-
sion levels of mRNA encoding mouse TNF-α and IL-1β
were measured according to manufacturer's protocol by
quantitative RT-PCR (StepOnePlus; Applied Biosystems)
by using specific assays-on-demand (Applied Biosys-
tems) target mixes. The expression levels were normal-
ized to ribosomal RNA and presented as fold change in
the expression ± SEM.
Statistical analysis
All data are given as mean ± SEM. For comparing means
of two treatment groups, two independent sample stu-
dent’s t-test was employed. For testing genotype and
treatment interaction, two-way ANOVA was employed.
For non-parametric data, Mann–Whitney U test was
employed to compare treatment medians. Two-step
cluster analysis was used to segregate microglia. All stat-
istical analysis were performed by GraphPad Prism ver-
sion 5.03 for Windows (GraphPad Software, La Jolla,
CA, USA, www.graphpad.com) and IBM SPSS statistics
version 19 for Windows (USA). Statistical significance
was set at P< 0.05.
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Results
Development of anti-human IgG antibodies due hIVIG
treatment in APdE9 mice
We treated APdE9 mice with hIVIG at 1 g/kg i.p. once
weekly starting at the age of 4 months, either for 3 months
or 8 months (Figure 1A). As expected, treatment resulted
in development of neutralizing antibodies. In the 3-
month study, we noticed that by the end of the treatment
all mice except only three had anti-human IgG titres
below 200. This observation led us to initially conclude
that mice will eventually develop immune tolerance.
However, our 8-month study clearly showed that this was
not the case. Anti-human IgG titres remained highly vari-
able irrespective of genotype (Figure 1 B and C). This is
in agreement with a recent report describing murine anti-
human antibody response of natural human antibodies in
a mouse model of Alzheimer’s disease [24]. However, it
was evident that brain penetration of hIVIG was not
affected by the magnitude of anti-human IgG titres. In
Figure 1D one can clearly see positive background immu-
nostaining for human IgG in the hippocampus and even
abutting putative plaques to a similar extent in mice with
low vs. high titres of neutralizing antibodies. Also, the
decoration of amyloid plaques by human IgG in both cor-
tex and hippocampus of a mouse (Figure 1E) that had the
highest anti-human IgG titres indicates that brain pene-
tration of hIVIG is not limited by the development of
anti-human antibodies. Lastly, stippled patterns of aggre-
gated material covered with human IgG immunoreactiv-
ity is specific to amyloid plaques as clearly demonstrated
in sections double stained with both anti-human IgG
immunostain and congo red histological stain (Figure 1F).
To further assess the contribution of neutralizing anti-
bodies to the results, we correlated the main measured
outcome parameters with anti-human antibodies. Serum
Aβ40 (r = 0.035, P= 0.91), hippocampal soluble Aβ40
(r = -0.11, P= 0.68), hippocampal CD45 immunoreactivity
(r = -0.29, P= 0.27), TNF-α (r = 0.01, P= 0.98) and Dou-
blecortin positive cells in the dentate gyrus (r = -0.11,
P= 0.76) all yielded statistically non-significant correla-
tions. Finally, among the 16 mice that received hIVIG
only seven mice produced significant titres of neutraliz-
ing antibodies (titres >200). After removing data from
these mice, the outcome of the study remained un-
changed. These data are presented in corresponding sec-
tions below.
Effects of hIVIG treatment on amyloid pathology in
APdE9 mice
Transgenic APdE9 mice treated for 3 months showed no
treatment effects compared to the saline group on either
soluble or insoluble Aβ40 or Aβ42 levels in the hippo-
campus or on serum Aβ40 levels (Table 1). Furthermore,
amyloid plaque burden in the hippocampus as visualized
by 6E10 antibody and Congo red stain did not differ be-
tween saline and hIVIG treated mice. Similarly, quantifi-
cation of CD45 immunostaining revealed no treatment
effects (Table 1). In contrast, APdE9 mice receiving the
same weekly hIVIG treatment for 8 months demon-
strated a significant elevation of soluble Aβ40 (t29 = 2.3,
P= 0.03) and Aβ42 (t29 = 2.8, P= 0.009) levels in the
hippocampus (Figure 2A and B). After removing data
from mice that produced significant titres of anti-human
antibodies, elevation of soluble Aβ42 levels still remained
significant (t22 = 2.2, P= 0.038). Insoluble Aβ40 and Aβ42
levels were also elevated but did not reach statistical sig-
nificance (P> 0.21; Figure 2C and D). In agreement with
this, immunohistochemical analysis of amyloid plaques
by W02 antibody (P= 0.37) and by Congo red staining
(P= 0.47) revealed no treatment differences (Figure 2E
and F). In addition, serum Aβ40 levels did not differ be-
tween the treatment groups (Figure 2G; P= 0.92), and
brain levels of Aβ40 and Aβ42 showed no correlation
with serum Aβ40 levels (r = 0.29, P= 0.31; r = 0.32,
P= 0.26, respectively). These data indicate a limited role
of peripheral sink as one of the mechanisms whereby
hIVIG can influence brain soluble Aβ levels.
Chronic hIVIG treatment suppresses microglia
We next went on to assess the nature of neuroinflamma-
tion associated with amyloid plaques in APdE9 mice
treated chronically for 8 months. Astrocyte reactivity as
measured by GFAP immunopositive area in hippocampi
did not differ between the treatment groups (Figure 3A).
Microglia/tissue macrophage reactivity in saline and
hIVIG treated mice was assessed by three markers: Iba-
1a, CD68, and CD45. Iba-1a is a structural marker for all
Table 1 Amyloid pathology and microglial reactivity after
3 months of hIVIG treatment in APdE9 mice
Measured parameter Treatments P value
Saline hIVIG
Serum Aβ40 (pg/μL) 0.56 ± 0.07 0.64 ± 0.07 0.67
Soluble Aβ42 (pg/mg) 0.36 ± 0.12 0.32 ± 0.05 0.74
Insoluble Aβ42 (ng/μL) 2.41 ± 0.25 2.43 ± 0.16 0.93
Aβ deposits (% 6E10
immunopositive area)
1.26 ± 0.08 1.20 ± 0.09 0.66
Fibrillar Aβ (% Congo red
positive area)
0.10 ± 0.01 0.12 ± 0.01 0.12
Microglia (% CD45
immunopositive area)
0.84 ± 0.06 0.83 ± 0.06 0.90
Four-month-old APP/PS1dE9 mice were treated with once weekly
intraperitoneal injection of either hIVIG (1 g/kg; n =16) or saline (n= 14) for
3 months. At the end of the treatment period, brains were extracted to assess
amyloid and microglial pathology. Serum Aβ40, soluble and insoluble Aβ42
were measured by ELISA. Aβ deposits and microglial activity were
quantitatively assessed from immunostainings whereas fibrillar amyloid was
assessed by quantifying Congo red histological stain. Data are represented as
mean ± SEM. Student’s t-test was employed to find treatment differences and
P< 0.05 was considered statistically significant.
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microglia, while CD45 is expressed more intensively in
infiltrating leukocytes compared to resident microglia.
Furthermore, increased expression of CD45 on resident
microglia indicates a phenotype of microglia activated
primarily by Aβ deposits. CD68 is a lysosomal marker
indicative of phagocytosis in microglia/macrophages
[2,25-27]. Whereas Iba-1a and CD68 markers revealed
no significant treatment effects (Figure 3B and C),
CD45 immunoreactivity was significantly decreased
(approximately 30%) in hIVIG treated mice (Figure 3D).
After removing data from mice that produced signifi-
cant titres of anti-human antibodies, the main out-
come, suppression of CD45 still remained significant
(t22 = 3.0, P= 0.0064). Moreover, this suppression corre-
lated inversely with elevated levels of soluble Aβ in the
hippocampus, indicating that these two effects of
chronic hIVIG treatment were interrelated (solu-
bleAβ42: r = -0.43, P= 0.02).
Chronic hIVIG treatment induces subtype specific changes
in microglia
A closer examination of Iba-1a and CD45 immunoposi-
tive cells revealed differences in their morphology and
location with regard to amyloid plaques. Iba-1a immu-
nopositive cells with variable staining intensity could be
found both in the immediate vicinity of amyloid plaques
(Figure 4A) and in areas free of plaques (Figure 4B). In
contrast, CD45 immunoreactivity was increased specific-
ally near amyloid plaques (Figure 4C). In addition, we
found small round, strongly CD45 positive cells ran-
domly distributed in the brain parenchyma (Figure 4D)
and in scattered dense clusters around brain blood ves-
sels (Figure 4E) and meninges (Figure 4F). It is reason-
able to hypothesize that these different populations of
Iba-1a or CD45 positive putative microglia and tissue
macrophages respond differentially to hIVIG treatment,
resulting in the observed decrease in the total CD45
signal.
In order to separate treatment effects in different cell
populations, we measured individual microglial cells on
confocal Z-stacks for their CD45 and Iba-1 intensities
(Figure 4G). The mean integrated intensities of CD45
and Iba-1 markers across the entire Z-axis of each micro-
glia were plotted against the circularity (morphological
parameter). This 3-D scatter plot visually identified three
different sub-populations of microglia as shown in Fig-
ure 5. Statistically, two-step cluster analysis as well
revealed three different clusters of cells with an average
silhouette equal to 0.7. In addition, the nonparametric
Kruskal-Wallis H-test rejected the null hypothesis (P
< 0.001) that there are no sub-populations of microglia.
We call these three clusters of cells simply as type A, B,
and C (Figure 5A). Type A cells seen in the plot have a
round soma with no processes, and exhibit very high
CD45 immunostaining intensity but negligible Iba-1a
staining. These cells correspond to round cells illu-
strated in Figure 4D and E). Their number increases
dramatically from 4 to 12 months of age, and much fas-
ter in APdE9 mice than in wild-type control mice (Fig-
ure 5B). Prima facie, they might be infiltrating immune
cells, although it is difficult to ascertain their exact per-
ipheral origin in this particular experimental setup.
Chronic hIVIG treatment did not significantly affect
CD45 expression in type A cells (U = 2,117, P= 0.99,
Mann–Whitney U test). Type B cells are characterized
by large oval cell bodies and thick branching processes,
and exhibit substantial CD45 and Iba-1 signal. These
cells are located in the immediate microenvironment of
amyloid plaques and likely represent activated microglia
around Aβ deposits [28]. Mann–Whitney U-test
revealed significantly reduced expression of CD45
(U= 15,605, P< 0.02) and elevated expression of Iba-1
(U= 13,972, P< 0.0001) in type B cells as a result of
chronic hIVIG treatment. Lastly, type C cells show much
more variable cell morphology. The cell bodies are rela-
tively small and the processes much thinner than in type
B cells. Type C cells exhibit substantial Iba-1a expres-
sion but practically no CD45 signal. These cells are
found equally often around Aβ deposits and in plaque-
free tissue. Those away from the plaques likely represent
cells referred to in the literature as quiescent microglia
[25,28,29]. Iba-1a expression was significantly elevated in
type C cells as a consequence of chronic hIVIG treat-
ment (U= 12,795, P= 0.0001). In hIVIG treated mice
type C microglial cells located away from amyloid
deposits were with comparatively longer and highly
ramified processes than those seen in saline treated
mice. Collectively, these observations indicate that
chronic hIVIG treatment brings about specific changes
in subpopulations of microglia/macrophages.
(See figure on previous page.)
Figure 2 Effects of chronic (8 months) hIVIG treatment on amyloid pathology in APdE9 mice. Brain samples were analyzed from 16 hIVIG
treated and 15 saline treated mice. Chronic hIVIG treatment elevated soluble Aβ40 (A) and Aβ42 (B) levels in the hippocampus. In contrast, levels
of hippocampal insoluble Aβ40 (C) and Aβ42 (D) levels did not change significantly. There was no significant treatment effect on amyloid load
(relative amyloid plaque area) in the hippocampus as visualized by WO2 antibody (E) or on dense core amyloid plaque area (F). Serum Aβ40
levels (G) in saline (n= 14) and hIVIG (n= 14) treated mice did not differ, either. All data are given as mean± SEM, * P< 0.05, ** P< 0.01 as
calculated by student’s t-test.
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Chronic hIVIG treatment suppresses TNF-α gene
expression
We further addressed the question of whether hIVIG ef-
fect on subpopulations of microglia/macrophages is
reflected in gene expression of pro-inflammatory cyto-
kines TNFα and IL-1β. Two-way ANOVA analysis of
gene expression profiles of these cytokines revealed signifi-
cant genotype (F1,33 = 34.3, P< 0.001) and treatment
(P=0.007) effects for TNF-α, but no significant interaction
between these factors (P=0.50; Figure 6A). As for IL-1β,
we noticed a significant genotype effect (F1,34 = 7.2,
P=0.01) but no treatment effect (P=0.79) or genotype by
treatment interaction (P=0.36; Figure 6 B). Interestingly,
in saline treated APdE9 mice there was a trend towards
positive correlation between TNF-α mRNA levels and
CD45 positive microglia (immunopositive area), while a
significant negative correlation was found between TNF-α






































































































Figure 3 Effects of chronic (8 months) hIVIG treatment on glial pathology in APdE9 mice. Immunostainings specific for astrocytes and
microglial cells were performed on free-floating brain sections. Panel shows representative images from hippocampi of saline (n= 15) and hIVIG
(n= 14-16) treated mice. (A) Astrocyte reactivity measured as GFAP immunoreactivity. (B) Microglial reactivity as measured as Iba-1
immunoreactivity. (C) Lysosomal marker CD68 immunoreativity. (D) Microglial activation as measured by CD45 immunoreactivity showed
significant differences between the treatments. Scale bars represent 200 μm. Data are given as mean± SEM. * P< 0.05, Student’s t-test. Scale bar
represents 200 μm.
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Figure 4 (See legend on next page.)
Puli et al. Journal of Neuroinflammation 2012, 9:105 Page 10 of 19
http://www.jneuroinflammation.com/content/9/1/105
(Figure 6E and F). Similar opposite correlations were
also observed between the treatment groups for IL-1β
(Figure 6G and H). These findings suggest that chronic
neuroinflammation around amyloid plaques in APdE9
mice is associated with a general increase in pro-in-
flammatory cytokines levels, while hIVIG specifically sup-
presses some cytokines such as TNFα.
Chronic hIVIG treatment augments neurogenesis
Finally, since involvement of microglia has been sug-
gested in hippocampal neurogenesis [30-35], we wanted
to assess whether chronic hIVIG treatment with select-
ive effects on some microglia/macrophage subpopula-
tions influences hippocampal neurogenesis. To this end,
we quantified doublecortin immunoreactivity in the den-
tate gyrus (DG) of the hippocampus (where adult neuro-
genesis is observed specifically in the subgranular zone).
Consistent with our previous unpublished findings,
barely any neurogenesis was present in the DG of saline
treated mice at the age of 12 months. However, a sub-
stantial number of doublecortin immunopositive neu-
rons could be observed in the DG of hIVIG treated mice
(Figure 6C and D). After removal of one outlier in the
hIVIG group, two-way ANOVA revealed a significant
main effects of treatment (F1,34 = 10.0, P= 0.003) and
genotype (F1,34 = 18.9, P= 0.0001) but no genotype by
treatment interaction (P= 0.30). Furthermore, CD45
positive microglia (immunopositive area) also showed a
significant negative correlation with the number of dou-
blecortin cells in the DG (Figure 6 I). These findings in-
dicate that chronic hIVIG treatment may preserve the
capacity of adult neurogenesis until a late age even in
the presence of amyloid pathology, and that this effect
may also be related to immunomodulation.
Discussion
Currently, human intravenous immunoglobulins (hIVIG)
are being tested in a Phase-3 clinical trial in mild to mod-
erate AD patients [36]. However, the mechanism of action
for hIVIG still remains elusive. In order to investigate
chronic in vivo effects of hIVIG, we treated APP/PS1dE9
transgenic mice with weekly injections for 3 months
and 8 months in separate studies. The shorter, 3-month
treatment duration, did not bring about any noticeable
changes in amyloid or microglial parameters. However,
the longer, 8-month treatment led to significant eleva-
tion of soluble hippocampal Aβ levels with no significant
changes in plaque-associated Aβ. Chronic treatment also
resulted in elevation of Iba-1 but suppressed CD45 mar-
ker in a subset of microglia/tissue macrophages and
reduced pro-inflammatory cytokine expression. In
addition, the chronic hIVIG treatment augmented
neurogenesis, the extent of which further correlated with
changes in the CD45 marker. These findings suggest that
long-term hIVIG treatment alters the brain neuroinflam-
matory response towards beneficial direction. In contrast
to our previous report, long-term hIVIG treatment in
APP/PS1 mice resulted in development of anti-human
antibodies. However, immunohistochemical presence of
human IgG inside cortex and hippocampus confirmed
brain penetration of hIVIG and together with re-
examination of statistical data after excluding mice
that developed neutralizing antibodies, indicate that
neutralizing anti-human antibodies made only a minor
contribution to the present results.
We used the most concentrated hIVIG preparation
available (1 g/kg) to maximize the dose of putative anti-
Aβ antibodies in this study. On the other hand, in a
human study on patients with mild AD, a lower dose
(0.4 g/kg) of hIVIG was found to be associated with
(See figure on previous page.)
Figure 4 Iba-1 and CD45 markers immunostain different phenotypes of microglial cells. Immunohistochemical detection with Iba-1
antibody identified microglia both near and away from amyloid deposits. (A) Activated microglia near and around Congo red positive amyloid
deposits (arrows) show increased Iba-1 expression and possess larger cell bodies with short thick processes. Typically, these activated microglia
cluster together forming a cordon around amyloid deposits. (B) Microglia away from or in between amyloid deposits (arrows) differ in
morphology from the previous type with respect to their smaller cell bodies and long thinner processes. These quiescent microglia typically
maintain distance from each other and are actively receiving inputs about their respective microenvironments [29] (C) The microglial marker CD
45 clearly identifies only activated microglia near amyloid deposits and possesses larger cell bodies with short thick processes. CD45 antibody
stained no microglia away from or in between Aβ deposits. (D) CD45 also identified many dark intensively stained round cells (arrows) which
were often found isolated or in groups inside brain parenchyma or near blood vessels (E) or meninges (F). (G) Phenotypes marked by both Iba-1
and CD45 can be seen together in a double fluorescent immunostaining. Maximun intensity projection of a confocal Z-stack revealed distinct Iba-1
(green) and CD45 (red) positive cell populations pointing to simultaneously co-existing different morphological phenotypes of activated and
resting microglia. Intensively stained iba-1 positive microglia (green) are seen as clumps (arrow) around a putative amyloid deposit. Some but not
all microglia (red) in clumps were also CD45 positive, thus producing a yellow signal indicative of co-localization. In contrast, quiescent microglia
away from putative amyloid deposits showed less intense Iba-1 (green) signal. This way it is feasible to simultaneously identify and quantify
microglial cells based on their morphological (circularity) and biochemical (Iba-1 and CD45 expression) attributes. Scale bars represent 500 μm
except for the confocal fluorescent image where it represents 50 μm.
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Figure 5 Chronic hIVIG treatment produces cell type specific changes in microglia. In order to assess whether chronic hIVIG treatment had
differential effects on morphologically discernible phenotypes of microglia, we analyzed expression of Iba-1 and CD45 on each individual
microglial cell along its entire X-Y-Z planes. Coronal sections of 35 μm were double stained with Iba-1 and CD45 primary antibodies followed by
attaching fluorescent secondary antibodies. We then acquired confocal Z-stack images from hippocampi of both saline and hIVIG treated mice.
After identifying and segregating the X-Y-Z boundaries of each microglial cell, a simple Image J macro measured the area, volume, and
integrated densities for Iba-1 and CD45 markers across its Z-axis. Circularity was measured using maximum intensity projection image for each of
the microglial stack. We analyzed 955 randomly chosen microglial cells spread across saline (n= 6) and hIVIG (n= 6) treated groups. (A) A 3-D
scatter plot of CD45 and Iba-1 integrated intensities, and circularity for each microglia cell type. Green circles represent the hIVIG group and blue
circles the saline group. Both visually and statistically, one can easily discern three clusters of cells which we designated as type A (n= 134; 14%),
type B (n= 386; 40.4%), and type C (n= 417; 43.6%). The right panels illustrate representative cells of each type. Round morphology and high
expression of CD45 alone characterizes type A cells. Type B cells features include ramified morphology with comparable expression of both CD45
and Iba-1 markers, whereas type C cells exhibit a ramified morphology but express predominantly Iba-1 marker. Scale bar = 5 μm. (B) The number
of CD45 positive round cells encountered in brain parenchyma (cortex and hippocampus) of APdE9 vs. wild-type mice at 2, 4, 10, 15, and
19 months of age (n= 2, at each age point). APdE9 mice exhibit a much more conspicuous age-dependent increase in the number of CD45
positive round cells than their wild-type littermates.
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higher MMSE scores than the high 1 g/kg dose, which
points to an inverted dose–response for in vivo hIVIG
effects [20]. Therefore, it appears logical to expect more
robust effects at a lower dose of hIVIG also in an AD
mouse model. However, our own studies in APP/PS1dE9
mice with either a low dose (0.1 g/kg) or shorter treat-
ment durations (1-3 weeks) yielded no effects on amyloid
or glial pathology. Moreover, our previous studies [21]
indicate that either a lower dose or a shorter treatment
duration do not yield a sufficient brain penetration of
hIVIG. Furthermore, the brain bioavailability of hIVIG is
likely to be much higher in aged humans than in young
adult mice and with intravenous administration as used
in human trial one may end up with a dose comparable
to intraperitoneal administration of the high dose used in
this study.
Human IVIG has been reported to possess antibodies
reactive not only to Aβ epitopes but also to Aβ conform-
ation [18]. Furthermore, both epitope and conformation
specific Aβ antibodies have been reported in sera from
healthy humans irrespective of age or gender [37]. These
antibodies present in hIVIG are hypothesized to aug-
ment the clearance of Aβ from the brains of APP/
PS1dE9 mice by various established mechanisms, such
as antibody mediated disaggregation of Aβ deposits,
antibody mediated microglial phagocytosis of Aβ depos-
its, and antibody mediated efflux of Aβ protein from
CNS into peripheral circulation due to peripheral sink.
Notably, all these mutually exclusive mechanisms should
ultimately result in decrease in brain total Aβ levels, and
the peripheral sink effect in addition may lead to an in-
crease in serum Aβ levels [38]. However, after 3 months
of treatment with hIVIG we noticed no change in either
brain or serum Aβ levels. This might be due to very low
concentration of anti-Aβ antibodies of the total IgG (ap-
proximately 0.1%, [18]) and insufficient accumulation in
the brain with a short duration of treatment. More sur-
prisingly, we noticed an elevation of soluble Aβ levels
with the present chronic 8-month treatment. The
underlying mechanisms for the selective elevation of sol-
uble Aβ levels is not clear at present, but interestingly,
microglia ablation in APP transgenic mice resulted in
similar changes in soluble Aβ levels [39]. Furthermore,
APP transgenic mice with CD45 deficiency also exhib-
ited elevation of soluble Aβ levels [40] and then in this
study, chronic hIVIG treatment caused suppression of
CD45 microglia marker by 30%, which correlated with
elevated soluble Aβ levels. This may be evidence for the
role of microglia in modulating the soluble levels of Aβ.
Nonetheless, this observation together with no changes
in insoluble (practically plaque-associated) Aβ clearly
points to an inefficient disintegration of pre-existing Aβ
deposits due to hIVIG treatment. Immunostainings with
N-terminal specific antibodies or Congo red staining for
fibrillar Aβ deposits also revealed no treatment effects.
Our 8-month study had an 80% power to detect a 19%
change in mean Aβ immunopositive area and 30%
change in mean Congo red positive area with a signifi-
cance level (alpha) of 0.05 (two-tailed). This together
with no changes in CD68 immunostaining speaks
against enhanced Aβ phagocytosis by microglia due to
hIVIG treatment.
According to the peripheral sink hypothesis, bidirec-
tional transfer of Aβ between CNS and periphery would
lead to elevated serum Aβ levels [41]. However, irre-
spective of the dose used or treatment duration, we
noticed no significant elevation of serum Aβ levels in
our studies. Furthermore, there was no correlation be-
tween brain Aβ and serum Aβ levels. Statistically, our
chronic 8-month study had an 80% power to detect a
22% change in mean serum Aβ40 levels with a signifi-
cance level (alpha) of 0.05 (two-tailed). Furthermore, in
our parallel unpublished studies no difference in amyloid
plaque burden or in biochemical levels of Aβ in brain
and serum was noticed after three weekly hIVIG injec-
tions in 3-month-old APP/PS1dE9 mice or after bi-
weekly hIVIG treatment for 3 weeks in 15-month-old
APP/PS1dE9 mice (data not shown). These findings
(See figure on previous page.)
Figure 6 Chronic hIVIG treatment decreases TNF-α gene expression and boosts neurogenesis. Frozen tissue samples from frontal cortices
of APdE9 and wild-type mice (n= 8-10) in saline and hIVIG groups were examined by quantitative RT-PCR for relative expression levels of TNF-α
(A) and IL-1β (B) mRNA (in comparison to expression levels of ribosomal RNA). Genotype and treatments effects were tested using two-way
ANOVA. (A) For TNF-α after removal of an outlier in hIVIG treated APdE9 group, significant genotype (***, P< 0.01), and treatment effects
(***, P< 0.01) were noticed albeit without any interaction. (B) IL-β showed only genotype differences (*, P< 0.05). (C) Representative images from
doublecortin stained hippocampal sections of wild-type and APdE9 transgenic mice treated for 8 months with saline or hIVIG. Scale bar represent
100 μm. (D) The doublecortin data are presented as mean± SEM (n= 10 mice in each group). After removal of an outlier in the hIVIG treated
APdE9 group, significant genotype (***, P< 0.01) and treatment effects (**, P< 0.01) emerged, with no significant interaction. (E) CD45 positive
microglia also showed a significant negative correlation with the number of doublecortin positive cells in the dentate gyrus (Spearman r = -0.50,
P= 0.02). Spearman correlation coefficient was used here to minimize the effect of two outliers. (F) Saline treated APdE9 mice showed a trend
towards positive correlation between CD45 microglia and TNF-α (Pearson r = 0.66; P= 0.05). (G) A significant negative correlation was observed
between CD45 microglia and TNF-α expression in hIVIG treated mice (Pearson r = -0.86; P= 0.003). (H) Similarly, relative levels of IL-β expression
showed a trend for positive correlation (Pearson r = 0.59; P= 0.09) in saline treated mice, whereas hIVIG treatment (I) brought about a significant
inverse correlation (Pearson r = -0.76; P= 0.01) between these two variables.
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indicate that the outcome of Aβ-related measurements
was not dependent on age or amyloid plaque burden
at the onset of hIVIG treatment. A recent in vivo
study reported that natural Aβ-antibodies (Nabs-Aβ)
isolated from hIVIG reduced amyloid plaque burden in
3-month-old mice but not in 12-month-old APP trans-
genic mice [24]. This reduction was ascribed to the
peripheral sink mechanism. However, even in that
study elevated plasma Aβ levels were not statistically
significant outcome of the treatment, and in the ab-
sence of correlations between brain/CSF and plasma
levels of Aβ, it will be difficult to acknowledge the
presence of a peripheral sink mechanism. Moreover,
the mere increase in plasma Aβ due to antibody treat-
ment might also be a consequence of stabilization of
Aβ-antibody complexes in plasma [42,43]. Interestingly,
a recently published report on monoclonal anti-Aβ im-
munotherapy (Bapineuzumab) indicates that in spite of
antibodies engaging brain Aβ, it may not necessarily
be reflected in CSF or serum [44].
Even though we found no amyloid reduction with
hIVIG, a recent in vivo study reported that natural Aβ-
antibodies (Nabs-Aβ) isolated from hIVIG confer protec-
tion from Aβ toxicity along with beneficial effects on
cognition in an APP transgenic mouse model of AD
[24]. However, in that report absence of an hIVIG trea-
ted group makes it difficult to delineate the effects of
constituent anti-Aβ antibodies and non-specific poly-
clonal IgG antibodies from those arising from extraction
procedure itself. As expected, 4 weeks of treatment with
natural Aβ-antibodies did not alter plaque pathology in
12-month-old mice but reduced amyloid plaque burden
in 3-month-old mice. However, the plaque reduction ef-
fect in young animals did not differ significantly between
low and high doses of Nabs-Aβ. In addition, a recent
meeting abstract also reported no significant changes in
PIB retention in brains of small number of human
patients treated with hIVIG [45]. Collectively, these find-
ings suggest that hIVIG unlikely would substantially
affect brain Aβ deposition or clearance.
After finding no evidence for amyloid lowering
mechanisms for hIVIG in our study, we shifted our
focus to anti-inflammatory actions of hIVIG. Anti-
inflammatory properties of hIVIG are well-known and
polyclonal antibodies of hIVIG are reactive to a wide
array of inflammatory proteins including cytokines and
chemokines [46]. Mean GFAP immunopositive area for
astrocyte reactivity was lower in hIVIG treated mice
than in the saline group, but failed to reach statistical
significance. A change in microglia phenotype (or acti-
vation state) was indicated by increased expression of
microglial markers around the Aβ microenvironment,
with CD45 measuring activated microglia [47] and Iba-1
measuring both activated and quiescent microglia. In
addition, the CD68 marker has been associated with
phagocytosis [2]. The lack of significant changes in
CD68 immunopositive microglia confirmed limited
effects of hIVIG treatment on Aβ phagocytosis. Whilst
8-month chronic hIVIG treatment suppressed CD45 ex-
pression, Iba-1 expression increased in a subset of
microglial cells as demonstrated by confocal analysis.
The fact that different subtypes of microglia cells
responded differently, strongly indicates that hIVIG has
a highly specific immunomodulatory effect and not just
a general suppression of the brain inflammatory reac-
tion. Notably, we measured Iba-1 signal from individual
microglial cells across their Z-axis, so there was no
interference from microglia in other activation levels
that could confound quantification of this signal. In
contrast, with nickel-DAB developed sections, the
immunopositive Iba-1 signal from microglia often are
influenced by neighboring microglial cells present in
various levels of activation. Thus, this approach allowed
us to measure integrated intensities of more than one
activation marker in a single individual microglial cell
and relate this information to their morphological fea-
tures (in this case, circularity). To our knowledge, this is
the first study to report segregation of microglial cells
based on both morphology and activation markers. A
change in microglial activation as a consequence of
hIVIG treatment has been reported in one previous
in vitro study [48]. In this study, BV-2 microglia cell line
displayed a more ramified morphology and increased
expression of CD45 in response to hIVIG treatment. In
contrast, our in vivo data finds decreased CD45 expres-
sion (only in Type B microglial cells) and increased Iba-
1 expression (in Type B and Type C microglial cells)
along with a shift towards more ramified microglia
morphology in hIVIG treated mice.
After finding clues for differential activation of micro-
glial cells, we focused further on classic inflammation
regulatory actions of hIVIG. Many in vitro and in vivo
studies have indicated the ability of hIVIG preparations
to modulate cytokine induction and release [49-56]. In
addition to direct cytokine neutralizing antibodies in
hIVIG, there are also other plausible mechanisms [57-
59]. Since pro-inflammatory cytokines like TNF-α and
IL-1β are important contributors of neuroinflammation,
there is an opportunity for hIVIG to cease, decrease, or
suppress amyloid induced cytokine release by microglia.
TNF-α gene expression has been reported to be
increased in various transgenic mouse models of AD, in-
cluding the APP/PS1dE9 mouse [60]. In our study,
hIVIG treatment caused a significant reduction in TNF-
α gene expression (and a similar trend in IL-1β expres-
sion). Moreover, this suppression of pro-inflammatory
gene expression due to hIVIG treatment was not geno-
type specific as it was also observed in wild-type
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littermates. One would expect a straightforward correl-
ation between the expression levels of pro-inflammatory
cytokines and CD45 marker of activated microglia. In-
deed, in saline treated mice, a trend towards positive
correlation was found between CD45 microglial marker
and TNF-α gene expression. However, chronic hIVIG
treatment shifted this correlation to opposite direction,
and a similar shift after hIVIG treatment was observed
in the correlation between CD45 and IL-1β gene ex-
pression. This inverse relationship between pro-inflam-
matory cytokine and CD45 expression suggests that
hIVIG treatment may change the brain immune re-
sponse such that microglia may maintain a high activity
despite a decrease in generalized inflammatory response
mediated through pro-inflammatory cytokines. This
profile of immunomodulation works against the profile
associated with aging [6] and may confer neuroprotec-
tion in the AD brain. Pro-inflammatory cytokine regula-
tory effects of hIVIG are further supported by a report
where circulating levels of TNF-α and IL-1β cytokines
dropped upon hIVIG treatment in Guillian-Barré syn-
drome patients [61]. More detailed experiments are still
needed to fully elucidate the mechanisms involved and
judge the therapeutic potential of cytokine regulatory
effects of hIVIG in the context of AD and other neuro-
degenerative pathologies.
Paucity of any previous studies pointing towards
neurogenesis by hIVIG compelled us to discuss this in-
directly. In fact in diverse experimental set-ups, many
studies connect suppression of microglia and pro-in-
flammatory markers to different stages in neurogenesis
[62-65]. Inflammation has been long known to be a
negative regulator of neurogenesis [32,34]. Cellular med-
iators of neuroinflammation, astrocytes and microglia,
may impact neurogenesis negatively via HPA axis
mediated release of glucocorticoids that suppress neuro-
genesis or by decreasing neurotrophin support or by
excessive release of reactive oxygen species and
pro-inflammatory cytokines [66,67]. In addition, pro-
inflammatory cytokines released by microglia are known
to play role in in vitro differentiation of hippocampal
progenitor cells [68]. Furthermore, in diverse animal
models of disease pro-inflammatory cytokines TNF-α
[34,69,70], IL-1β [71,72], IFN-α [73], and IL-6 [34,74]
have been shown to suppress adult neurogenesis, while
in one study blockade of IL-6 alone restored it [34]. In
the context of AD, neurogenesis has been extensively
studied in various transgenic Alzheimer mouse models,
and Aβ itself has been shown to suppress adult neuro-
genesis in the hippocampus [75]. Strikingly, in our AD
mouse model, chronic hIVIG treatment not only altered
activation status of microglia and suppressed pro-inflam-
matory TNFα gene expression, but also significantly
enhanced the number of doublecortin positive cells in
the dentate gyrus irrespective of the genotype of mice.
This effect may be selectively beneficial for aged mice in
which neurogenesis is about to fade out. Moreover, the
negative correlation between CD45 microglia and num-
ber of doublecortin positive cells in our study also points
towards an inverse relationship between activated micro-
glia and neurogenesis. While microglial cells activated by
TNF-α and IL-6 inhibited neurogenesis, microglial cells
activated by IL-4 and T-cells have also been reported to
contribute to hippocampal neurogenesis [76,77]. Such al-
ternatively activated microglia were shown to express
MHCII proteins and co-localize with IGF-1, a growth
factor known for neuroprotection and neurogenesis
[78,79]. Therefore, modulation of microglia by hIVIG
and subsequent suppression of pro-inflammatory cyto-
kines might restore and foster hippocampal neurogen-
esis, thereby representing a mechanism to compensate
for the loss of neurons observed during AD progression.
However, it is also possible that fostering neurogenesis
might be a direct exclusive property of hIVIG, irrespect-
ive of other indirect mechanisms discussed here.
Our study was designed to test amyloidocentric
mechanisms for hIVIG but we clearly present evidence
for hIVIG effects independent of Aβ clearance. This is
the first passive immunotherapy report in AD transgenic
mice that describes modulation of microglial activation,
suppression of pro-inflammatory cytokine gene expres-
sion, and enhancement of neurogenesis as a conse-
quence of hIVIG treatment independent of amyloid
clearance in the brain. However, it is unclear whether
these are mutually exclusive and independent effects.
This combination of effects makes hIVIG a unique drug
candidate that targets multiple inflammatory antigens
and immunomodulatory factors associated with neuro-
genesis [80]. It will be interesting to investigate if mere
modulation of CD45 microglial protein expression could
as well change cytokine profiles and support neurogen-
esis. A recent report described alterations in plasma
cytokines levels in mild to moderate AD patients treated
chronically with hIVIG, and further that these changes
correlated with clinical outcomes, suggesting that immu-
nomodulation by cytokines may be one of the thera-
peutic mechanisms for hIVIG [81]. While Aβ
(oligomers) delivers the kiss of death by 1,000 tiny blows
to neurons [82], hIVIG reserves the potential to deliver
relief by plethora of mechanisms [83] such as influen-
cing the activation state of microglia, suppressing pro-
inflammatory gene expression, immunomodulation,
regulating cytokine networks, and fostering neurogenesis
in a manner independent of constituent anti-Aβ anti-
bodies. Therefore, enriching hIVIG preparations with
anti-Aβ antibodies may not be necessary to unmask the
beneficial effects of hIVIG. In view of the limited supply
of hIVIG [84] it will be of enormous benefit to further
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explore the anti-inflammatory, immunomodulatory, and
neurogenic mechanisms of hIVIG in the context of Alz-
heimer’s pathology [85].
Conclusions
We found no in vivo support of Aβ clearance from
the brains of hIVIG treated transgenic mice either
due to disintegration or phagocytosis. We also found
no evidence for existence of peripheral sink as mech-
anism for Aβ clearance in hIVIG treated mice. How-
ever, we succeeded to segregate microglia population
based on their morphology and Iba-1/CD45 markers,
and observed hIVIG treatment effects in these spe-
cific subpopulations of microglia. Treatment with
hIVIG suppressed TNF-α gene expression and fos-
tered neurogenesis in the dentate gyrus. Our data
show limited capacity of hIVIG to alleviate Aβ path-
ology but provides experimental evidence for immu-
nomodulatory effects.
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